1. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28(2):169-80.
2. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367-75.
3. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. J Clin Orthop Trauma. 2021;17:88-93.
4. Ertuğrul MB, Baktıroğlu S, Aksoy M, Çalangu S. Diyabetik Ayak ve İnfeksiyonu. Klimik Derg. 2004;17(1):3-12.
5. Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023;330(1):62-75.
6. Fanaroff AC, Yang L, Nathan AS, et al. Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. J Am Heart Assoc. 2021;10(17):e021456.
7. Ertugrul MB. Diyabetik Ayak İnfeksiyonları. Türkiye Klinikleri J Gen Surg-Special Topics. 2010;3(1):46 – 56
8. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg. 2006;117(7 Suppl):212S-38S.
9. Yesil S, Akinci B, Bayraktar F, et al. Reduction of major amputations after starting a multidisciplinary diabetic foot care team: single centre experience from Turkey. Exp Clin Endocrinol
Diabetes. 2009;117(7):345-9.
10. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol.
2011;5(6):1591-5.
11. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52(7):1799-
805.
12. Acosta JB, del Barco DG, Vera DC, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J. 2008;5(4):530-9.
13. Berlanga-Acosta J, Mendoza-Mari Y, Martinez MD, Valdes-Perez C, Ojalvo AG, Armstrong DG. Expression of cell proliferation cycle negative regulators in fibroblasts of an ischemic diabetic
foot ulcer. A clinical case report. Int Wound J. 2013;10(2):232-6.
14. Fleissner F, Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal. 2011;15(4):933-48.
15. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007;127(3):526-37.
16. Fu K, Zheng X, Chen Y, et al. Role of matrix metalloproteinases in diabetic foot ulcers: Potential therapeutic targets. Front Pharmacol. 2022;13:1050630.
17. Tardaguila-Garcia A, Garcia-Morales E, Garcia-Alamino JM, Alvaro-Afonso FJ, Molines-Barroso RJ, Lazaro-Martinez JL. Metalloproteinases in chronic and acute wounds: A systematic
review and meta-analysis. Wound Repair Regen. 2019;27(4):415-20.
18. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008;16(1):37-44.
19. Berlanga-Acosta J. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J. 2011;8(6):612-20.
20. Oncul O, Yildiz S, Gurer US, et al. Effect of the function of polymorphonuclear leukocytes and interleukin-1 beta on wound healing in patients with diabetic foot infections. J Infect.
2007;54(3):250-6.
21. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885-910.
22. Monteiro-Soares M, Hamilton EJ, Russell DA, et al. Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2023:e3648.
23. Lipsky BA, Senneville E, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36 Suppl
1:e3280.
24. Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes Metab Res Rev.
2023:e3687.
25. Saltoğlu N, Kılıçoğlu Ö, Baktıroğlu S. Diyabetik Ayak Yarası ve İnfeksiyonunun Tanısı, Tedavisi ve Önlenmesi: Ulusal Uzlaşı Raporu. Klimik Derg. 2015;28(Suppl 1):2-34.
26. Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007;4(4):286-7.
27. Ertugrul BM, Oncul O, Tulek N, et al. A prospective, multi-center study: factors related to the management of diabetic foot infections. Eur J Clin Microbiol Infect Dis. 2012;31(9):2345-52.
28. Ertugrul B, Uckay I, Schoni M, Peter-Riesch B, Lipsky BA. Management of diabetic foot infections in the light of recent literature and new international guidelines. Expert Rev Anti Infect Ther.
2020;18(4):293-305.
29. Ertuğrul MB, Baktıroğlu S. Diyabetik Ayak ve Osteomiyeliti. Klimik Derg. 2005;18(1):8-13.
30. Ertugrul MB, Baktiroglu S, Salman S, et al. The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labelled leucocyte scanning.
Diabet Med. 2006;23(6):649-53.
31. Ertugrul MB, Baktiroglu S, Salman S, et al. Pathogens isolated from deep soft tissue and bone in patients with diabetic foot infections. J Am Podiatr Med Assoc. 2008;98(4):290-5.
32. Ertugrul BM, Savk O, Ozturk B, Cobanoglu M, Oncu S, Sakarya S. The diagnosis of diabetic foot osteomyelitis: examination findings and laboratory values. Med Sci Monit. 2009;15(6):CR307-
12.
33. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis.
2012;54(12):e132-73.
34. Ertugrul BM, Lipsky BA, Savk O. Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem. Diabet Foot Ankle. 2013;4.
35. Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023.
36. Cildag MB, Ertugrul BM, Koseoglu OF, Cildag S, Armstrong DG. Angiographic assessment of atherosclerotic load at the lower extremity in patients with diabetic foot and charcot neuro-arth-
ropathy. J Chin Med Assoc. 2018;81(6):565-70.
37. Cildag MB, Ertugrul MB, Koseoglu OFK. Charcot Neuroarthropathy and a New Sign: “Soft Tissue Contamination Sign of Foot or Ankle” on Bolus Chase 3-Dimensional Magnetic Resonance
Imaging. J Foot Ankle Surg. 2020;59(3):643-4.
38. Hatipoglu M, Mutluoglu M, Uzun G, Karabacak E, Turhan V, Lipsky BA. The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections
in Turkey. Eur J Clin Microbiol Infect Dis. 2014;33(6):871-8.
39. Ertuğrul MB, Uyar-Güleç G, Baktıroğlu S, Çörekli E, Türe M. Diyabetik Ayak İnfeksiyonu Etkenlerinin Yıllara Göre Dağılımı; Değişim Var mı? Klimik Derg. 2017;30(1):27-31.
40. Saltoglu N, Ergonul O, Tulek N, et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. Int J Infect Dis. 2018;70:10-4.
41. Surme S, Saltoglu N, Kurt AF, et al. Changing Bacterial Etiology and Antimicrobial Resistance Profiles as Prognostic Determinants of Diabetic Foot Infections: A Ten-Year Retrospective Cohort
Study. Surg Infect (Larchmt). 2022;23(7):667-74.
42. Utlu Y, Başak O, Bozkurt-Kozan F, Ertuğrul MB. Causative Agents and Factors Associated With Multidrug Resistant Pathogens in Diabetic Foot Infections. Klimik J. 2019;32(1):84 – 9.
43. Acar A, Saltoglu N, Tulek N, et al. Impact of the Covid-19 Pandemic on Diabetic Foot Patients. Journal of the American Podiatric Medical Association. 2024;Article in press.
44. Ertugrul BM, Oryasin E, Lipsky BA, Willke A, Bozdogan B. Virulence genes fliC, toxA and phzS are common among Pseudomonas aeruginosa isolates from diabetic foot infections. Infect
Dis (Lond). 2018;50(4):273-9.
45. Hatipoglu M, Mutluoglu M, Turhan V, et al. Causative pathogens and antibiotic resistance in diabetic foot infections: A prospective multi-center study. J Diabetes Complications. 2016;30(5):910-
6.
46. Saltoglu N, Surme S, Ezirmik E, et al. The Effects of Antimicrobial Resistance and the Compatibility of Initial Antibiotic Treatment on Clinical Outcomes in Patients With Diabetic Foot
Infection. Int J Low Extrem Wounds. 2023;22(2):283-90.
47. Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract.
2007;75(1):47-50.
48. Yates C, May K, Hale T, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907-9.
49. Bristow IR, Spruce MC. Fungal foot infection, cellulitis and diabetes: a review. Diabet Med. 2009;26(5):548-51.
50. Mutluoglu M, Uzun G, Turhan V, Gorenek L, Ay H, Lipsky BA. How reliable are cultures of specimens from superficial swabs compared with those of deep tissue in patients with diabetic foot
ulcers? J Diabetes Complications. 2012;26(3):225-9.
51. Kessler L, Piemont Y, Ortega F, et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med. 2006;23(1):99-
102.
52. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis.
2006;42(1):57-62.
53. Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004;21(7):705-9.
54. Ertugrul MB. Diyabetik ayak infeksiyonunda medikal tedavi. TOTBİD Derg. 2015;15:404 – 12.
55. Ertugrul BM, Lipsky BA, Ture M, Sakarya S. Risk Factors for Infection with Pseudomonas aeruginosa in Diabetic Foot Infections. J Am Podiatr Med Assoc. 2017;107(6):483-9.
56. Arda B, Uysal S, Tasbakan M, et al. Use of Tigecycline for Diabetic Foot Infections. Wounds. 2017;29(11):297-305.
57. Öztürk ŞB, Ertuğrul MB, Çörekli E. Diyabetik ayak enfeksiyonlarında etken bakteriler ve biyofilm oluşturma oranları. Türk Mikrobiyol Cem Derg. 2017;47(1):33 – 8.
58. Aktaş Ş, Ertuğrul MB. Diyabetik aya ve kronik yaralarda biyofilm. In: Sakarya S, ed. Biyofilm Enfeksiyonları. 1. Baskı ed. Ankara: Türkiye Klinikleri; 2018:26-32.
59. Eren Kutlusoy OÖ, Öztürk ŞB. Diyabetik ayak enfekte yarada biyofilm bir kader mi? In: Mutlu M, Ertuğrul MB, eds. Diyabeti Ayak Problemleri, Enfeksiyonlar ve Charcot Nöroosteoartropa-
tisi. 1. Baskı ed. Ankara: Türkiye Klinikleri; 2020:50-4.
60. Ozturk B, Gunay N, Ertugrul BM, Sakarya S. Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in
vitro biofilm model. Can J Microbiol. 2016;62(9):735-43.
61. Cimsit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther. 2009;7(8):1015-26.
62. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing,
lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999;7(5):335-46.
63. Ertugrul BM, Buke C, Ersoy OS, Ay B, Demirez DS, Savk O. Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey. Diabet Foot Ankle. 2015;6:28419.
64. Ertugrul BM, Lipsky BA, Guvenc U, Turkish Intralesional Epidermal Growth Factor Study Group for Diabetic Foot W. An Assessment of Intralesional Epidermal Growth Factor for Treating
Diabetic Foot Wounds(The First Experiences in Turkey). J Am Podiatr Med Assoc. 2017;107(1):17-29.
65. Ertugrul MB, Yapar N, Tasbakan M, et al. Evaluation of the efficacy and safety of topical epidermal growth factor Regen-D® in diabetic foot wounds: a randomised, parallel group phase III
study. The Diabetic Foot Journal. 2021;24(2):52.
66. Alves PJ, Barreto RT, Barrois BM, Gryson LG, Meaume S, Monstrey SJ. Update on the role of antiseptics in the management of chronic wounds with critical colonisation and/or biofilm. Int
Wound J. 2021;18(3):342-58.
67. Babalska ZL, Korbecka-Paczkowska M, Karpinski TM. Wound Antiseptics and European Guidelines for Antiseptic Application in Wound Treatment. Pharmaceuticals (Basel). 2021;14(12).
68. Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother. 2008;61(6):1281-7.
69. Sakarya S, Gunay N, Karakulak M, Ozturk B, Ertugrul B. Hypochlorous Acid: an ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. Wounds.
2014;26(12):342-50.
70. Venturi ML, Attinger CE, Mesbahi AN, Hess CL, Graw KS. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol. 2005;6(3):185-
94.
71. Gottrup F, Apelqvist J. Present and new techniques and devices in the treatment of DFU: a critical review of evidence. Diabetes Metab Res Rev. 2012;28 Suppl 1:64-71.
72. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev. 2008(3):CD001898.
73. Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2023:e3686.
74. Bus SA, Armstrong DG, Crews RT, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2023:e3647.
75. Mumcuoglu KY, Taylan Ozkan A. [The treatment of suppurative chronic wounds with maggot debridement therapy]. Turkiye Parazitol Derg. 2009;33(4):307-15.
76. Tombulturk FK, Kanigur-Sultuybek G. A molecular approach to maggot debridement therapy with Lucilia sericata and its excretions/secretions in wound healing. Wound Repair Regen.